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Gender stratified adjustment of the DAS28-CRP
improves inter-score agreement with the DAS28-ESR
in rheumatoid arthritis
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Neil McHugh4 and John D. Pauling4,5 on behalf of the BSRBR-RA Contributors
Group
Abstract
Objectives. To evaluate determinants of discordance between DAS28-ESR and DAS28-CRP and resulting impact on
disease activity stratification in RA.
Methods. Paired DAS28-ESR and DAS28-CRP readings (n= 31 074) were obtained from the British Society for
Rheumatology Biologics Register for RA. Factors influencing discordance between DAS28-ESR and DAS28-CRP were
evaluated alongside the resulting effect on disease activity stratification. The impact of gender adjustment to the DAS28-
CRP was evaluated.
Results. DAS28-CRP scores were 0.3 lower than DAS28-ESR overall, with greatest differences for women (0.35)
and patients over 50 years old (0.34). Mean male DAS28-CRP scores were 0.15 less than corresponding DAS28-ESR
scores. Discordance between DAS28-ESR and DAS28-CRP significantly impacted disease activity stratification at low
disease activity and remission thresholds (32.0% and 66.6% concordance, respectively). Adjusting DAS28-CRP scores
by gender significantly (P< 0.001) improved agreement with the DAS28-ESR.
Conclusion. Discordance between DAS28-ESR and DAS28-CRP is greatest for women and patients over 50 years of
age, and influences disease activity stratification. The proposed gender-adjusted DAS28-CRP improves inter-score
agreement with DAS28-ESR, supporting more reliable disease activity stratification in treat-to-target approaches for RA.
Key words: RA, DAS28, CRP, ESR, DAS, BSRBR, biologics, gender, age, BMI
Rheumatology key messages
. On average, DAS28-ESR generates scores 0.3 greater than the DAS28-CRP.
. The difference between the DAS28-CRP and DAS28-ESR is greater for women and patients over 50.
. Adjusting the DAS28-CRP according to gender significantly reduces inter-score differences with the DAS28-ESR.
Introduction
Disease activity in RA is commonly measured using the
28-joint count DAS (DAS28), a composite index incorpor-
ating a tender joint count, swollen joint count, patient
global assessment and markers of inflammatory
response. The original DAS28 was developed and vali-
dated using the ESR [1, 2]. Original development of the
DAS28-CRP followed assessment of paired samples ob-
tained from a relatively small cohort of 334 patients with
subsequent wide adoption in clinical practice and trial
settings [3]. ACR and EULAR do not differentiate between
the two versions of the score when using disease activity
thresholds. This results in the two versions of the score
being used interchangeably in clinical practice (and obser-
vational studies that rely on data captured in clinical
practice), with identical disease activity stratification
thresholds adopted in assessment of disease activity,
treatment response and treat-to-target approaches.
Disparity in DAS28-CRP and DAS28-ESR values could
also influence patient management where high-cost drug
reimbursement is only permitted if specific disease activity
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thresholds are reached. In the UK access to biologics is
dependent on patients having a DAS28 score of >5.1 on
two successive occasions at least 1 month apart [4].
Therefore, discrepancies between scoring methods may
delay the availability of biologic DMARDs to patients, with
potential negative consequences on quality of life, func-
tion and radiographic progression. Many studies have
highlighted consistently lower DAS28-CRP compared
with DAS28-ESR scores, at both lower levels of disease
activity that form the focus of treat-to-target management
[59] and high disease activity [10]. It is acknowledged
that ESR values are generally higher in females and in-
crease with age [11], while the CRP is not affected by
these factors. ESR and CRP levels may also be differen-
tially affected by BMI. Understanding the relative impact
of gender, age and BMI on inter-score differences may
help improve agreement between the DAS28-CRP and
DAS28-ESR such that both instruments could be used
interchangeably.
We report an analysis from the British Society of
Rheumatology Biologics Register for RA (BSRBR-RA)
using real-world data, exploring discordance between
the DAS28-CRP and DAS28-ESR, and resulting impact
on disease activity stratification in RA. We propose that
the DAS28-CRP should be adjusted depending on
gender.
Methods
Study population
The BSRBR-RA is a national, prospective, longitudinal,
observational study examining long-term safety of bio-
logic agents in patients with RA in the UK. Ethical approval
was obtained from the Multicentre Research Ethics
Committee for the North-West of England. All patients en-
rolled provided written informed consent.
Subject selection and data collection
The methods of the BSRBR-RA have been described pre-
viously [12]. Patients treated with biologic therapy with
concurrent measures of ESR and CRP were identified
from the BSRBR-RA, enabling paired calculation of
DAS28-ESR and DAS28-CRP using existing formulae
[13]. Because of NICE requirements, baseline DAS28
scores for participants of the BSRBR-RA are mostly
>5.1. Therefore, data obtained at baseline and following
treatment with biologic agents were used in the initial
cohort analysis. Data from patients taking tocilizumab
were excluded due to specific effects of IL-6 on serum
CRP levels [14].
Statistical analysis
The impact of age, baseline BMI and gender on concord-
ance between DAS28-ESR and DAS28-CRP was as-
sessed by dichotomizing the group for age (5 or <50
years) and gender, and stratifying BMI according to
World Health Organization thresholds [15]. This analysis
focused on the agreement between two methods of mea-
suring an outcome (i.e. the DAS28-CRP and DAS28-ESR),
rather than changes in an outcome with repeated within-
subject measurements. Accordingly, repeated measure-
ments were not adjusted for. A random effects model
was used to allow for the possibility that ESR and CRP
were not measured from the same blood sample (e.g. at
the same time). Age at enrolment to the BSRBR-RA was
used where it was not possible to calculate the age at time
when the DAS28 score was measured.
Agreement between the scores was compared using
BlandAltman statistics. Descriptive analysis was applied
to compare disease stratification within accepted DAS28
disease activity thresholds. The cohort was subsequently
subdivided according to gender. DAS28-CRP scores
were differentially adjusted according to the inter-score
differences identified in the initial analysis, and subse-
quent inter-score differences were compared. Kappa
values and root mean squared error quantified agreement
and mean error of DAS28-CRP and subsequent adjusted
DAS28-CRP scores [16]. The differences in mean errors
between the DAS28-ESR and DAS28-CRP or adjusted
DAS28-CRP were compared using the Wilcoxon signed
rank test.
Results
Subject characteristics
Paired ESR and CRP values were available for 8509 sub-
jects, with 31 074 paired assessments (Supplementary
Table S1, available at Rheumatology online). The majority
of subjects were female (76%), with mean (S.D.) age of
57.3 (12.2) years and a mean (S.D.) baseline disease dur-
ation of 12.7 (9.6) years.
Discordance between DAS28-ESR and DAS28-CRP
The DAS28-CRP was on average 0.3 points lower than the
corresponding DAS28-ESR for the whole cohort. When
stratifying by age and gender, differences between the
two scores were more pronounced for women and pa-
tients aged over 50 (0.35 points for both). The mean
DAS28-CRP score in males was only 0.15 points less
than the corresponding DAS28-ESR score. Mean inter-
score differences did not alter when categorized by base-
line BMI (Table 1).
Impact of disparity between DAS28-ESR and DAS28-
CRP on disease activity stratification
Disparity between the DAS28-ESR and DAS28-CRP had a
significant impact on disease stratification, particularly
within the low disease activity category where the two
scores only agreed in 32.0% of cases (Table 2). The
DAS28-ESR classified fewer patients in remission com-
pared with the DAS28-CRP, and more in high disease
activity (Supplementary Table S2, available at
Rheumatology online).
Adjusting DAS28-CRP according to gender
Subdividing the cohort by gender and adjusting DAS28-
CRP scores by +0.35 for females and +0.15 for men sig-
nificantly reduced inter-score differences overall
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(P< 0.001 for females and males), and for age and BMI
strata (Table 1). Inter-score disease activity classification
improved for remission, low and moderate disease activ-
ities, with only a very minor reduction in agreement at high
disease activity (3.9% and 0.7% for females and males
respectively; Table 2). Root mean squared error reduced
from 0.62 to 0.51 DAS28 points for females and from 0.58
to 0.56 for men and kappa was increased for females
(from 0.61 to 0.69) and males (from 0.66 to 0.69) when
baseline DAS28-CRP scores were adjusted according to
gender.
Discussion
This study agrees with existing evidence suggesting
DAS28-ESR and DAS28-CRP should not be viewed as
interchangeable outcome measures, highlighting the limi-
tations of doing so, with important consequences for clin-
ical and research practice [510]. We have proposed a
novel and practical method for improving agreement be-
tween the two indices that could be applied in future ob-
servational studies and clinical practice where both
methods have been applied at different time points.
Initial development of the DAS28-CRP by Fransen et al.
[3], which included data from 334 patients, used linear
regression and high Pearson correlation coefficient to
suggest equivalence with the DAS28-ESR. However, at
that time, agreement analysis was not undertaken.
Subsequent analyses by Wells et al. [17] demonstrated
the DAS28-CRP to be a valid outcome measure, although
inter-score discrepancies were identified. Consequently,
while correlation between the scores was high, equiva-
lence and interchangeability were not demonstrated.
Disparity between DAS28-ESR and DAS28-CRP has led
some to propose applying lower disease activity thresh-
olds for the DAS28-CRP [6, 7, 10]. However, this ap-
proach does not take into account the differential impact
of age and gender between the two DAS28 scores.
Furthermore, changing disease activity thresholds of the
DAS28-CRP would necessitate updating all guidance
where reference is made only to the ‘DAS28’ without spe-
cification as to the version used, and require clinicians to
familiarize themselves with two different stratification
systems.
We have demonstrated that variation in equivalence be-
tween the two scores is most pronounced for older pa-
tients and women (demographics representing the
majority of the RA population) and at lower disease activ-
ity levels (the target for most treatment strategies). This
discordance precludes easy comparison of outcomes of
studies that have adopted different versions of the DAS28.
The impact of BMI was lower than expected and correc-
tion for BMI to improve agreement between the two
scores is not necessary. It is possible that other factors
(including comorbidities) may affect the relationship be-
tween ESR and CRP measurements. However, limiting
the additional data required (gender) to improve inter-
score agreement means these findings can be translated
to use in clinical and research settings easily.T
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We propose that adjusting DAS28-CRP scores by +0.35
points for females and +0.15 points for males would sig-
nificantly improve inter-score agreement, and allow exist-
ing disease activity thresholds to be used without
modification. This adjustment takes into account
observed biological differences in ESR levels between fe-
males and males and is straightforward and practical.
Improvement in agreement of disease activity stratifica-
tion at lower disease activity thresholds is achieved at the
expense of a minor reduction in agreement at high dis-
ease activity; the effect of which would be to encourage
more active treatment for patients with higher disease ac-
tivity, in line with current treatment paradigms. Adjustment
of the DAS28-CRP based on age was considered, but the
time-varying nature of age makes this a less practical ad-
justment to the score.
A potential limitation is that we used a single cohort for
our study. However, patients included in the BSRBR-RA
are enrolled from across the UK, representing a broad
population and spectrum of RA management. The
cohort is mainly of Caucasian ethnicity, which may influ-
ence ESR and CRP relationships differently compared
with other ethnicities [8, 9]. The main cohort included pa-
tients on biologic agents recruited to a registry, which may
introduce selection bias, although it is unlikely this would
impact on ESR/CRP comparisons. It is possible unknown
confounders may influence whether an individual has both
an ESR and CRP test undertaken rather than only one.
There were some missing data, although there were no
significant demographic differences between missing and
complete groups (Supplementary Table S3, available at
Rheumatology online).
Our findings suggest the DAS28-ESR and DAS28-CRP
should not be used interchangeably when stratifying dis-
ease activity. Gender influences inter-score agreement,
and adjustment of the DAS28-CRP according to gender
significantly improves inter-score reliability.
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